Skip to main content
. 2019 Mar 15;79(5):555–562. doi: 10.1007/s40265-019-01095-z

Table 2.

Culture conversion by month 6 in the CONVERT trial [13]

ALIS + GBT GBT alone Adjusted odds ratio
Total no. of patients (ITT population) 224 112
Patients with culture conversiona (%) 65 (29.0*) 10 (8.9) 4.22 (95% CI 2.08–8.57)

ALIS amikacin liposome inhalation suspension, GBT guidelines-based therapy, ITT intent-to-treat

*p < 0.001 vs. GBT alone

aCulture conversion defined as having three consecutive monthly Mycobacterium avium complex-negative sputum cultures by month 6